Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2021 - 2026)

Tarsus Pharmaceuticals' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 7.76% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 4.33% increase from a year earlier, with the FY2025 full-year figure at $15.7 million, up 4.88% from the prior year.
• Interest & Investment Income slipped to $3.7 million in Q1 2026 per TARS's latest filing, from $4.0 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.2 million in Q2 2025 and bottomed at $297000.0 in Q2 2022.
• The 5-year median for Interest & Investment Income is $3.3 million (2024), against an average of $3.0 million.
• Across the five-year window, Interest & Investment Income jumped 13162.5% in 2022 and fell 0.15% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $2.1 million in 2022, then jumped by 40.01% to $3.0 million in 2023, then grew by 22.46% to $3.6 million in 2024, then climbed by 8.31% to $4.0 million in 2025, then decreased by 5.77% to $3.7 million in 2026.
• Per Business Quant, the three latest TARS Interest & Investment Income figures stand at $3.7 million (Q1 2026), $4.0 million (Q4 2025), and $4.1 million (Q3 2025).